A newly observed COVID-19 variant, informally called “Cicada” and identified as BA.3.2, has begun appearing in several countries and U.S. states. Its emergence has renewed interest among researchers, not because of immediate danger, but because of its unusual characteristics.

The nickname reflects its slow, prolonged circulation. First detected in late 2024, the variant remained at low levels before becoming more noticeable in early 2026. Such delayed visibility is not uncommon, though rising detection across regions tends to draw attention.

Scientists are closely examining its genetic makeup. BA.3.2 carries many mutations in the spike protein, setting it apart from variants that have dominated recently. Early lab findings suggest that antibodies from prior infection or vaccination may not recognize it as efficiently.
In some places, BA.3.2 has increased in proportion among sequenced cases, which may point to an advantage in transmitting through populations with high existing immunity. Still, shifts in prevalence do not automatically signal larger impact and remain under evaluation.
Current evidence does not show that this variant causes more severe illness. Symptoms reported so far—such as sore throat, congestion, fatigue, and cough—resemble those of other recent strains, with no clear signs of greater intensity.